Speaker Profile
M.D., Chief Development Officer, Tempus AI
Biography
Dr. Halla Nimeiri serves as the Chief Development Officer of Oncology at Tempus. Prior to Tempus, she held clinical development positions at Foundation Medicine and AbbVie. Dr. Nimeiri is a dedicated oncologist. She brings expertise in clinical trial design, drug development, and precision oncology. Dr. Nimeiri is an active academic clinician at Feinberg School of Medicine, where she provided transformative patient care for over 10 years. Dr. Nimeiri earned her dual fellowship in HematologyOncology from The University of Chicago.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Adrian Lee, UPMC
PMWC Award Ceremony
• Dennis J. Slamon, UCLA
• Arul M. Chinnaiyan, University of Michigan
Keynote
• Dennis J. Slamon, UCLA
Keynote: From Cancer Drivers to Clinical Decisions: Transforming Tumor Genomics into Therapy Guidance
• Arul M. Chinnaiyan, University of Michigan
Serial ctDNA-Guided Therapy Switching (SERENA-6 & Beyond)
• Chair: Adrian Lee, UPMC
• Pedram Razavi, MSK
• Minetta Liu, Natera
• Christian Rolfo, Ohio State
Neoadjuvant to Adjuvant MRD: How Early Is Early Enough?
• Chair: Angela DeMichele, UPenn
• Halla Nimeiri, Tempus
• Aparna Parikh, Harvard
• Minetta Liu, Natera
• Christopher Lieu, University of Colorado
Rapid MRD to Treatment Decisions: Standardized ctDNA at Scale
• Chair: Luca Quagliata, Thermo Fisher
• Christian Rolfo, Ohio State
Multi-Omics Monitoring Beyond Variants: Methylation, Fragmentomics, EV/ctRNA
• David T. Miyamoto, Massachusetts General Hospital
• Maximilian Diehn, Stanford
• Daniel De Carvalho, University of Toronto
• Arul M. Chinnaiyan, University of Michigan
From Detection to Direction: Whole-Genome MRD for Therapy Guidance at Scale
• Phil Febbo, Veracyte
From Validation to Payment: Coverage Pathways That Work
• Chair: Mark Stewart, Friends of Cancer Research
• Hilary Gee Goeckner, American Cancer Society (ACS)
• Sally Werner, Cancer Support Community
• Gabriel A. Bien-Willner, Palmetto GBA
